$BCRX
BIOCRYST PHARMACEUTICALS INC

2021 Q3 Form 10-Q Financial Statement

#000117184321005674 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $40.99M $49.96M $2.871M
YoY Change 571.81% 1640.13% 98.27%
Cost Of Revenue $591.0K $297.0K $0.00
YoY Change -61.04%
Gross Profit $40.40M $49.66M $2.871M
YoY Change 781.2% 1629.78% 98.27%
Gross Profit Margin 98.56% 99.41% 100.0%
Selling, General & Admin $34.99M $26.33M $13.88M
YoY Change 103.5% 89.62% 60.33%
% of Gross Profit 86.61% 53.01% 483.56%
Research & Development $49.97M $52.87M $27.50M
YoY Change 65.22% 92.28% -0.66%
% of Gross Profit 123.68% 106.47% 957.78%
Depreciation & Amortization $229.0K $197.0K $180.0K
YoY Change 34.71% 9.44% 0.0%
% of Gross Profit 0.57% 0.4% 6.27%
Operating Expenses $84.96M $79.20M $41.38M
YoY Change 79.1% 91.39% 13.87%
Operating Profit -$44.58M -$29.58M -$38.51M
YoY Change 4.01% -23.18% 10.29%
Interest Expense $14.12M $13.50M $2.918M
YoY Change 382.23% 362.47% -3.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$58.80M -$43.20M -$38.61M
YoY Change 27.5% 11.88% 2.6%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$58.80M -$43.20M -$38.61M
YoY Change 27.51% 11.89% 2.6%
Net Earnings / Revenue -143.44% -86.47% -1344.72%
Basic Earnings Per Share -$0.33 -$0.24
Diluted Earnings Per Share -$328.3K -$0.24 -$239.0K
COMMON SHARES
Basic Shares Outstanding 178.9M 178.1M shares 154.3M
Diluted Shares Outstanding 179.1K 178.1M shares 161.6K

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $199.6M $218.4M $189.4M
YoY Change 39.27% 15.32% 105.54%
Cash & Equivalents $199.6M $210.3M $173.5M
Short-Term Investments $0.00 $8.114M $15.94M
Other Short-Term Assets $13.27M $9.908M $5.200M
YoY Change 79.34% 90.54% -24.64%
Inventory $13.66M $9.846M $5.233M
Prepaid Expenses
Receivables $26.21M $27.62M $3.997M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $252.7M $265.8M $203.8M
YoY Change 55.6% 30.4% 96.53%
LONG-TERM ASSETS
Property, Plant & Equipment $7.829M $7.669M $7.149M
YoY Change 9.62% 7.27% -5.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.191M $3.813M $3.720M
YoY Change 42.38% 2.5% -14.15%
Total Long-Term Assets $13.02M $11.48M $10.87M
YoY Change -5.58% 5.64% -13.91%
TOTAL ASSETS
Total Short-Term Assets $252.7M $265.8M $203.8M
Total Long-Term Assets $13.02M $11.48M $10.87M
Total Assets $265.8M $277.3M $214.7M
YoY Change 50.81% 29.15% 84.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.69M $10.09M $9.354M
YoY Change 69.53% 7.84% 12.73%
Accrued Expenses $56.31M $48.77M $24.84M
YoY Change 84.85% 96.29% 28.43%
Deferred Revenue
YoY Change
Short-Term Debt $30.00M $30.00M $29.80M
YoY Change 0.33% 0.67% 1.71%
Long-Term Debt Due $19.10M
YoY Change
Total Short-Term Liabilities $133.6M $115.6M $102.7M
YoY Change 19.53% 12.62% 42.67%
LONG-TERM LIABILITIES
Long-Term Debt $132.1M $126.8M $31.70M
YoY Change 390.89% 299.99% -36.35%
Other Long-Term Liabilities $5.035M $4.100M $3.800M
YoY Change 29.1% 7.89% 1.55%
Total Long-Term Liabilities $132.1M $126.8M $35.50M
YoY Change 328.73% 257.17% 848.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $133.6M $115.6M $102.7M
Total Long-Term Liabilities $132.1M $126.8M $35.50M
Total Liabilities $265.7M $242.4M $138.2M
YoY Change 86.3% 75.4% 82.59%
SHAREHOLDERS EQUITY
Retained Earnings -$1.190B -$1.131B -$916.8M
YoY Change 23.55% 23.35% 14.54%
Common Stock $1.798M $1.787M $1.764M
YoY Change 1.81% 1.3% 59.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$147.0M -$106.1M $76.51M
YoY Change
Total Liabilities & Shareholders Equity $265.8M $277.3M $214.7M
YoY Change 50.81% 29.15% 84.54%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$58.80M -$43.20M -$38.61M
YoY Change 27.51% 11.89% 2.6%
Depreciation, Depletion And Amortization $229.0K $197.0K $180.0K
YoY Change 34.71% 9.44% 0.0%
Cash From Operating Activities -$23.28M -$25.41M -$31.04M
YoY Change -39.16% -18.13% 26.69%
INVESTING ACTIVITIES
Capital Expenditures -$365.0K -$812.0K -$70.00K
YoY Change 114.71% 1060.0% -22.22%
Acquisitions
YoY Change
Other Investing Activities $8.112M $5.319M -$4.860M
YoY Change -123.94% -209.44% -121.73%
Cash From Investing Activities $7.747M $4.507M -$4.930M
YoY Change -122.75% -191.42% -122.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.776M 4.574M 108.2M
YoY Change -203.15% -95.77% 26287.8%
NET CHANGE
Cash From Operating Activities -23.28M -25.41M -31.04M
Cash From Investing Activities 7.747M 4.507M -4.930M
Cash From Financing Activities 4.776M 4.574M 108.2M
Net Change In Cash -10.75M -16.33M 72.22M
YoY Change -86.03% -122.61% -4090.06%
FREE CASH FLOW
Cash From Operating Activities -$23.28M -$25.41M -$31.04M
Capital Expenditures -$365.0K -$812.0K -$70.00K
Free Cash Flow -$22.91M -$24.60M -$30.97M
YoY Change -39.85% -20.57% 26.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
178869928
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
277284000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334715000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49959000 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
178725000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
178725000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176883000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176883000
CY2020Q2 bcrx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3511000
CY2020Q2 us-gaap Advertising Expense
AdvertisingExpense
0 USD
us-gaap Advertising Expense
AdvertisingExpense
0 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210314000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272127000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4348000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2221000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
8114000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28239000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27620000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8646000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
9846000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7039000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5560000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
265802000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
323800000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7669000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7113000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3813000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3802000 USD
CY2021Q2 us-gaap Assets
Assets
277284000 USD
CY2020Q4 us-gaap Assets
Assets
334715000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10087000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18713000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48765000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33942000 USD
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
25217000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21670000 USD
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
551000 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
150000 USD
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
981000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1179000 USD
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
30000000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
30000000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
115601000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
105654000 USD
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4100000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3871000 USD
CY2021Q2 bcrx Future Royalties Payable
FutureRoyaltiesPayable
136862000 USD
CY2020Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
124717000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
126796000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
119735000 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2871000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69018000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7694000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-19262000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6220000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-80959000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-79488000 USD
CY2021Q2 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
13000 USD
CY2020Q2 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
2758000 USD
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
39000 USD
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
10000 USD
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
69000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
79541000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
41381000 USD
us-gaap Costs And Expenses
CostsAndExpenses
149977000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1787000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1769000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1022975000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1002408000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1130924000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1023442000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-106075000 USD
us-gaap Costs And Expenses
CostsAndExpenses
87182000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29582000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38510000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52873000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27498000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95308000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57365000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26325000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13883000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48439000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29748000 USD
CY2021Q2 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
46000 USD
CY2020Q2 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
0 USD
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
9204000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
13495000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
2918000 USD
us-gaap Interest Expense
InterestExpense
26399000 USD
us-gaap Interest Expense
InterestExpense
5965000 USD
CY2021Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-134000 USD
CY2020Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
63000 USD
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-163000 USD
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
43000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43198000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-38607000 USD
us-gaap Net Income Loss
NetIncomeLoss
-107482000 USD
us-gaap Net Income Loss
NetIncomeLoss
-76206000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-92000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
86000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-36000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43293000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38618000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-107398000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76242000 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-240
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-240
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-600
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-480
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178127
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161569
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177737
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157862
us-gaap Net Income Loss
NetIncomeLoss
-107482000 USD
us-gaap Net Income Loss
NetIncomeLoss
-76206000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
377000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
401000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13111000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6034000 USD
bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
15604000 USD
bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
0 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
7459000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
bcrx Increase Decrease In Amortization Of Debt Issuance Costs
IncreaseDecreaseInAmortizationOfDebtIssuanceCosts
-399000 USD
bcrx Increase Decrease In Amortization Of Debt Issuance Costs
IncreaseDecreaseInAmortizationOfDebtIssuanceCosts
681000 USD
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
34000 USD
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
104000 USD
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-0 USD
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-590000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
18976000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-18149000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2809000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5233000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-817000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2743000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1156000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3547000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2902000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
403000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1405000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86422000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54322000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
912000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
187000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
-0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
15438000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
20089000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21417000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19177000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5792000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92848000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14817000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7474000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
798000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7474000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108463000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-59686000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59933000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
274348000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115723000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
214662000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175656000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
38252000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37599000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-25000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
266000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2754000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3648000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-38607000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
532000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92848000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-19262000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-64284000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
179000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
723000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2177000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5479000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-74988000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43198000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-95000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4574000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7632000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-106075000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14817000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3280000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
76507000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
8111000 USD
CY2021Q2 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
2000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
8114000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
28211000 USD
CY2020Q4 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
25000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
28239000 USD
CY2021Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
6513000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8243000 USD
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
4990000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
206000 USD
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
4597000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2555000 USD
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
529000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4548000 USD
CY2021Q2 us-gaap Inventory Gross
InventoryGross
10116000 USD
CY2020Q4 us-gaap Inventory Gross
InventoryGross
7309000 USD
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
270000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
270000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
9846000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7039000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
1000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
1000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49959000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2871000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69018000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7694000 USD
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
1800000 USD
us-gaap Advertising Expense
AdvertisingExpense
3204000 USD
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
13495000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
26399000 USD
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2918000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5965000 USD
CY2021Q2 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
154000 USD
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
211000 USD
CY2020Q2 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
341000 USD
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
681000 USD
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27419
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14007
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25871
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12963
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, the ORLADEYO royalty financing and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y6M
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128 pure
us-gaap Operating Lease Expense
OperatingLeaseExpense
913000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
935000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
819000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
841000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
606000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
969000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
834000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
655000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
581000 USD
CY2021Q2 bcrx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
7327000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10972000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5891000 USD
CY2021Q2 bcrx Operating Lease Rightofuse Asset Accumulated Amortization
OperatingLeaseRightofuseAssetAccumulatedAmortization
2111000 USD
CY2020Q4 bcrx Operating Lease Rightofuse Asset Accumulated Amortization
OperatingLeaseRightofuseAssetAccumulatedAmortization
2641000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22044
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.50
CY2020Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
108096000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13111000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6034000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
60067000 USD
CY2021Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
11248000 USD
CY2021Q2 bcrx Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
20080000 USD
CY2021Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
15347000 USD
CY2021Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
12525000 USD
CY2021Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
867000 USD

Files In Submission

Name View Source Status
0001171843-21-005674-index-headers.html Edgar Link pending
0001171843-21-005674-index.html Edgar Link pending
0001171843-21-005674.txt Edgar Link pending
0001171843-21-005674-xbrl.zip Edgar Link pending
bcrx-20210630.xsd Edgar Link pending
bcrx-20210630_cal.xml Edgar Link unprocessable
bcrx-20210630_def.xml Edgar Link unprocessable
bcrx-20210630_lab.xml Edgar Link unprocessable
bcrx-20210630_pre.xml Edgar Link unprocessable
bcrx20210630_10q.htm Edgar Link pending
bcrx20210630_10q_htm.xml Edgar Link completed
exh103_01.jpg Edgar Link pending
exh103_02.jpg Edgar Link pending
exh104logo.jpg Edgar Link pending
ex_270086.htm Edgar Link pending
ex_270087.htm Edgar Link pending
ex_270088.htm Edgar Link pending
ex_270089.htm Edgar Link pending
ex_272063.htm Edgar Link pending
ex_272109.htm Edgar Link pending
ex_272110.htm Edgar Link pending
ex_272111.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending